[Administration of a new antimycobacterial combined therapy in leprosy in East Africa].
D000351:Africa, Eastern; D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003622:Dapsone / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D007918:Leprosy / Q000188:drug therapy*; D008297:Male; D011379:Prognosis; D011719:Pyrazines / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D013424:Sulfanilamides / Q000627:therapeutic use; D013997:Time Factors
D000995:Antitubercular Agents; D011719:Pyrazines; D013424:Sulfanilamides; D003622:Dapsone; D007538:Isoniazid; D012293:Rifampin
Die Anwendung einer neuen antimykobakteriellen Kombinationstherapie bei der Lepra in Ostafrika.